For the quarter ended December 2025, Zimmer Biomet (ZBH) reported revenue of $2.24 billion, up 10.9% over the same period last year. EPS came in at $2.42, compared to $2.31 in the year-ago quarter.
The reported revenue represents a surprise of +1.87% over the Zacks Consensus Estimate of $2.2 billion. With the consensus EPS estimate being $2.38, the EPS surprise was +1.7%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Zimmer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Knees- United States: $519.6 million versus the four-analyst average estimate of $504.26 million. The reported number represents a year-over-year change of +6%.
- Net Sales- Hips- United States: $293.2 million versus $287.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
- Net Sales- Hips- International: $262.2 million compared to the $268.17 million average estimate based on four analysts. The reported number represents a change of +5.6% year over year.
- Net Sales- Knees- International: $391.4 million versus $379.91 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.1% change.
- Net Sales- International: $931.2 million compared to the $919.34 million average estimate based on three analysts. The reported number represents a change of +10.6% year over year.
- Net Sales- United States: $1.31 billion versus the three-analyst average estimate of $1.29 billion. The reported number represents a year-over-year change of +11.1%.
- Net Sales- Knees: $911 million compared to the $886.42 million average estimate based on seven analysts. The reported number represents a change of +8.6% year over year.
- Net Sales- Technology & Data, Bone Cement and Surgical: $189.8 million versus the seven-analyst average estimate of $189.56 million.
- Net Sales- S.E.T: $587.6 million versus $584.44 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +20.1% change.
- Net Sales- Hips: $555.4 million versus the seven-analyst average estimate of $551.15 million. The reported number represents a year-over-year change of +6.8%.
View all Key Company Metrics for Zimmer here>>>
Shares of Zimmer have returned -1.9% over the past month versus the Zacks S&P 500 composite's no change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
